Partnering and Collaborations

4SC is focused on developing small molecule drugs for the treatment of cancer. Through development partnerships with pharmaceutical and biotech companies as well as academia and clinics we aim to accelerate the development process and achieve market approval for our drug candidates and their availability to patients with cancer.

For our core drug candidates; resminostat, domatinostat and 4SC-208 we are open for partnering or collaborations with:

  • Pharmaceutical companies to support further clinical development and/or to commercialize products after completing regulatory filings
  • Investigators and clinical sites interested in performing investigator sponsored studies / research with our drug candidates either as monotherapy or in combination to improve existing therapies in cancer
  • Biotech and Pharmaceutical companies to develop novel assets in synergy with our drug candidates
  • Academia to support our pre-clinical efforts

If you are interested in collaborating with 4SC, please email hidden; JavaScript is required.

Partners and licensees

In May 2016, 4SC and Guangzhou Link Health Pharma Co., Ltd (Link Health, Guangzhou, China) entered into an exclusive licensing and development agreement for 4SC-205 in China, Hong Kong, Taiwan and Macao. Link Health is responsible for performing and financing the clinical development of 4SC-205, regulatory approval and regional product marketing. The data generated may be used by 4SC to support further development of 4SC-205 in other key markets such as Europe or the U.S. Under this agreement, 4SC received an up-front payment, and is eligible for further development milestones and royalties.

Press Release

Share this page:

Follow us on: